Narinder Pal Bhalla Sells 22,306 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider directly owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Trading Up 5.4%

Shares of Lexeo Therapeutics stock opened at $4.69 on Friday. The firm has a market capitalization of $368.26 million, a PE ratio of -3.23 and a beta of 1.42. The business’s 50-day moving average price is $5.09 and its 200-day moving average price is $6.60. Lexeo Therapeutics, Inc. has a 12 month low of $3.60 and a 12 month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. As a group, analysts predict that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LXEO. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a report on Monday, May 11th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Institutional Trading of Lexeo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LXEO. Allworth Financial LP boosted its stake in shares of Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after purchasing an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Lexeo Therapeutics in the fourth quarter worth $37,000. California State Teachers Retirement System raised its holdings in Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in Lexeo Therapeutics during the 2nd quarter valued at $50,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.